Complement activation pathways associated with islet cell surface antibody (ICSA) derived from child patients with insulin-dependent diabetes mellitus (IDDM).
We studied the pathways of complement activation associated with the islet cell surface antibody (ICSA) obtained from sera of 7 patients (age less than 15 years) with insulin dependent diabetes mellitus (IDDM). The target cells were 51CR labelled rat islet cells and the complement source was human AB serum. Complement-dependent antibody mediated cytotoxicity (CAMC activity) was obtained using the percentage of cytotoxicity. CAMC activity of untreated sera was significantly inhibited by treating with EGTA or EDTA (p less than 0.001). The CAMC activity of EDTA-treated sera was significantly lower than that of EGTA-treated sera (p less than 0.001). In the inactivated human AB serum, it was lower than that of EGTA-treated sera (p less than 0.05), but not different from that of EDTA-treated sera. These results show that the complement activation associated with ICSA in patients occurred not only via the classical pathway but also via the alternative pathway.
Okada
S
S
Third Department of Internal Medicine, Okayama University Medical School, Japan.
Ichiki
K
K
Sato
K
K
Tanokuchi
S
S
Ishii
K
K
Hamada
H
H
Ota
Z
Z
D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D000954:Antigens, Surface / Q000502:physiology*; D002648:Child; D003167:Complement Activation / Q000502:physiology*; D003165:Complement System Proteins / Q000502:physiology; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D004492:Edetic Acid / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D005260:Female; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology*; D008297:Male
D000954:Antigens, Surface; D004533:Egtazic Acid; D003165:Complement System Proteins; D004492:Edetic Acid